Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor Positive，HER2-negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT05104866
What this trial is testing

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Who this might be right for
Breast Cancer
AstraZeneca 732
Testing effectiveness (Phase 2)Active Not RecruitingNCT02738866
What this trial is testing

Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor

Who this might be right for
Metastatic Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 60
Post-approval studies (Phase 4)Study completedNCT02679755
What this trial is testing

Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Breast Cancer
Pfizer 252
Large-scale testing (Phase 3)Study completedNCT01610284
What this trial is testing

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 1,147
Not applicableLooking for participantsNCT06534125
What this trial is testing

Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+2 more
Emory University 150
Early research (Phase 1)Study completedNCT04134884
What this trial is testing

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerTriple Negative Breast CancerHormone Receptor Positive Tumor
Kathy Miller 34
Large-scale testing (Phase 3)Active Not RecruitingNCT04862663
What this trial is testing

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Who this might be right for
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca 893
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07716046
What this trial is testing

Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer

Who this might be right for
Breast CancerHER2-positive Breast CancerHormone Receptor-positive Breast Cancer+1 more
Fudan University 240
Testing effectiveness (Phase 2)Ended earlyNCT05554354
What this trial is testing

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Negative Breast CarcinomaMetastatic Hormone Receptor-Positive Breast Carcinoma
National Cancer Institute (NCI) 1
Testing effectiveness (Phase 2)Looking for participantsNCT06341894
What this trial is testing

Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer

Who this might be right for
Early Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 1,163
Testing effectiveness (Phase 2)Study completedNCT02760030
What this trial is testing

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

Who this might be right for
Estrogen Receptor and/or Progesterone Receptor PositiveHER2/Neu NegativeStage IA Breast Cancer+6 more
Ohio State University Comprehensive Cancer Center 14
Testing effectiveness (Phase 2)Study completedNCT00696072
What this trial is testing

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Who this might be right for
Metastatic Breast Cancer
Bristol-Myers Squibb 120
Early research (Phase 1)Study completedNCT06253195
What this trial is testing

BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorHormone-receptor-positive Breast Cancer+4 more
BeOne Medicines 33
Very early researchStudy completedNCT04130152
What this trial is testing

Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 22
Testing effectiveness (Phase 2)Study completedNCT03477396
What this trial is testing

Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor and/or Progesterone Receptor PositiveHER2/Neu NegativeStage IV Breast Cancer AJCC v6 and v7
City of Hope Medical Center 2
Early research (Phase 1)Study completedNCT02586675
What this trial is testing

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

Who this might be right for
Breast CancerBreast Cancer - FemaleBreast Cancer - Male
H. Lee Moffitt Cancer Center and Research Institute 7
Early research (Phase 1)Active Not RecruitingNCT02779751
What this trial is testing

Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

Who this might be right for
Non Small Cell Lung CancerBreast Cancer
Eli Lilly and Company 100
Not applicableNot Yet RecruitingNCT07701070
What this trial is testing

SHIELD: Surveillance of HR+/HER2- : Implementing ESR1m Long-term Monitoring and Detection in 1L aBC

Who this might be right for
Advanced Breast Cancer
AstraZeneca 3,000
Testing effectiveness (Phase 2)Study completedNCT04596150
What this trial is testing

Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

Who this might be right for
NeoplasmsBreast NeoplasmsBreast Neoplasms, Triple-Negative+2 more
CytomX Therapeutics 125
Testing effectiveness (Phase 2)Looking for participantsNCT04348747
What this trial is testing

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Malignant Neoplasm in the BrainMetastatic Triple-Negative Breast Carcinoma+1 more
Roswell Park Cancer Institute 23
Next Page